Venetoclax Extension Study
Phase 3
Recruiting
- Conditions
- Multiple Myeloma
- Registration Number
- JPRN-jRCT2051220047
- Lead Sponsor
- Sumiko Okubo
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 550
Inclusion Criteria
Subject has been enrolled and dosed in an ongoing venetoclax study and continues to tolerate and derive benefit from the study drug.
- Male subject agrees to refrain from sperm donation.
- Female subjects must not be pregnant or breastfeeding.
Exclusion Criteria
- None
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Adverse Events
- Secondary Outcome Measures
Name Time Method